Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Gene Biotherapeutics, Inc. | Financial_Report.xls |
| 10-K - FORM 10-K - Gene Biotherapeutics, Inc. | d269381d10k.htm |
| EX-32 - SECTION 1350 CERTIFICATION - Gene Biotherapeutics, Inc. | d269381dex32.htm |
| EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - SECTION 302 - Gene Biotherapeutics, Inc. | d269381dex312.htm |
| EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SECTION 302 - Gene Biotherapeutics, Inc. | d269381dex311.htm |
| EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Gene Biotherapeutics, Inc. | d269381dex211.htm |
| EX-10.33 - STRATEGIC PARTNERSHIP AGREEMENT - Gene Biotherapeutics, Inc. | d269381dex1033.htm |
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statements of Cardium Therapeutics, Inc. and subsidiaries (the “Company”) on Form S-3 (File Numbers 333-131104, 333-141664, 333-145479, 333-147947 and 333-168693) and on Form S-8 (File Numbers 333-138666 and 333-142823) of our report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, dated March 30, 2012, with respect to our audits of the consolidated financial statements of Cardium Therapeutics, Inc. and subsidiaries as of December 31, 2011 and 2010 and for the years ended December 31, 2011 and 2010 and for the period from December 22, 2003 (date of inception) through December 31, 2011, which reports are included in this Annual Report on Form 10-K of Cardium Therapeutics, Inc. and subsidiaries for the year ended December 31, 2011.
/s/ Marcum LLP
Marcum LLP
New York, New York
March 30, 2012